Email this article 
Hide
Show all
Review Article
Hepatitis B co-infection in HIV-infected patients receiving antiretroviral therapy at the TC Newman Anti Retroviral Treatment Clinic in Paarl, Western Cape
Submitted: 07 January 2015 | Published: 20 May 2016
About the author(s)
Jeanmari King, Division of Family Medicine and Primary Care, Stellenbosch University, South Africa; District Health Services, Western Cape Department of Health, South AfricaDirk T. Hagemeister, Department of Family Medicine, University of the Free State, South Africa; Universitas Academic Hospital, Bloemfontein, South Africa
Abstract
Background: Hepatitis B virus (HBV) and human immunodeficiency virus (HIV) co-infection in South Africa is estimated to be between 5% and 23%; however, only limited evidence is available. Co-infection increases the risk of chronification of HBV, liver cirrhosis and death.
Objective: To assess the HBV and/or HIV co-infection rate amongst the adult antiretroviral treatment cohort at the TC Newman ART Clinic in Paarl, Western Cape.
Methods: In a retrospective, cross-sectional study, the routine hepatitis B surface antigen screening results for all adult HIV patients who were started on antiretroviral treatment over a period of 19 months were collected and analysed for gender, CD4 count and age.
Results: Amongst the 498 participants (60% female participants), the Hepatitis B surface Antigen positivity rate was 7.6%. Male gender, age between 50 and 59 years and a low CD4 count were correlated with higher rates.
Conclusion: Useful insight could be obtained by analysing routine data. The prevalence of almost 8% confirms the need for testing of HIV-positive patients for hepatitis B.
Keywords: hepatitis B; prevalence; HIV-infected; adults; co-infection
Keywords
Metrics
Total abstract views: 4566Total article views: 12760
Crossref Citations
1. Investigation of mutations in the partial sequences of the surface and polymerase genes of hepatitis B virus associated with immune escape and drug resistance in HIV-infected patients
Lorato Modise, Nomathamsanqa Sithebe, Hazel Mufhandu
F1000Research vol: 12 first page: 1232 year: 2025
doi: 10.12688/f1000research.132498.4
2. Investigation of hepatitis B virus mutations associated with immune escape and drug resistance in human immunodeficiency virus-infected patients
Lorato Modise, Nomathamsanqa Sithebe, Hazel Mufhandu
F1000Research vol: 12 first page: 1232 year: 2024
doi: 10.12688/f1000research.132498.2
3. Prevalence and characteristics of hepatitis B and D virus infections among HIV-positive individuals in Southwestern Nigeria
Oluyinka Oladele Opaleye, Olusola Anuoluwapo Akanbi, Folakemi Abiodun Osundare, Bo Wang, Olufisayo Adesina, Adeolu Sunday Oluremi, Sola Thomas Sunday, Abiodun Akeem Akindele, Patrycja Klink, C. Thomas Bock
Virology Journal vol: 18 issue: 1 year: 2021
doi: 10.1186/s12985-021-01493-4
4. Hepatitis B virus infection in patients presenting for immunosuppressive cancer therapy with and without underlying HIV infection
Malowane H. Ngoato, Edina Amponsah-Dacosta, Ntombifuthi Blose, Selokela G. Selabe, Thembeni L. Msibi, Mojakgomo H. Motswaledi, Andrew M. Musyoki
Frontiers in Virology vol: 3 year: 2023
doi: 10.3389/fviro.2023.1160078
5. Susceptibility to hepatitis B infection, hepatitis B/HIV co-infections and hepatitis B immunity in HIV-positive patients starting HAART in Durban, South Africa
FM Chonco, S Rangiah
South African Family Practice vol: 61 issue: 2 first page: 65 year: 2019
doi: 10.1080/20786190.2018.1518023
6. Investigation of hepatitis B virus mutations associated with immune escape and drug resistance in human immunodeficiency virus-infected patients
Lorato Modise, Nomathamsanqa Sithebe, Hazel Mufhandu
F1000Research vol: 12 first page: 1232 year: 2023
doi: 10.12688/f1000research.132498.1
7. Investigation of hepatitis B virus mutations associated with immune escape and drug resistance in human immunodeficiency virus-infected patients
Lorato Modise, Nomathamsanqa Sithebe, Hazel Mufhandu
F1000Research vol: 12 first page: 1232 year: 2025
doi: 10.12688/f1000research.132498.3
8. Outcomes and characteristics of patients on protease inhibitors at a tertiary level antiretroviral clinic
Michele Perks, Denasha L. Reddy, Francois Venter
Southern African Journal of HIV Medicine vol: 24 issue: 1 year: 2023
doi: 10.4102/sajhivmed.v24i1.1536
9. The Role of Transforming Growth Factor Beta-1 in the Progression of HIV/AIDS and Development of Non-AIDS-Defining Fibrotic Disorders
Annette J. Theron, Ronald Anderson, Theresa M. Rossouw, Helen C. Steel
Frontiers in Immunology vol: 8 year: 2017
doi: 10.3389/fimmu.2017.01461